Customer Name: Phenotype: Cytochrome P450 1A2 genotype: Collection Date:
Reviewed by: Lily Nguyen, Product Manager
Laboratory Director (s): Chinh Bach, Ph.D.
Laboratory Test Interpretative Comments: The liver is responsible for the metabolism of caffeine via cytochrome P450 1A2 enzyme. Caffeine can be broken down quickly or slowly depending on what variant gene a person has. Rapid caffeine metabolism is indicative of 2 copies of the fast variant (CYP1A2*1A). These individuals are referred as "fast" caffeine metabolizers. In contrast, slow caffeine metabolism is a result of the slow variant (CYP1A2*1F). These individuals are "slow" caffeine metabolizers, and will either be homozygous (2 copies of slow variant) or heterozygous (1 copy of slow and 1copy of fast variant). "Slow" caffeine metabolizers:
• Homozygous for CYP1A2*1F/*1F or heterozygous for CYP1A2*1A/*1F
• Risk of nonfatal heart attack increases by 36% when consuming 2-3 cups of coffee a day, and
consumption of 4 or more cups per day will elevate the nonfatal heart attack risk by 64% [1]
• Individuals under 50 years of age who are "slow" caffeine metabolizers, and drink 4 or more cups of
coffee per day may increase their nonfatal heart attack risks by fourfold! [1]
• "Slow" caffeine metabolizers are likely to be harmed than benefit from drinking excessive coffee or
other caffeinated drinks; therefore, precautions regarding the amount of caffeine consumption should be considered for one's wellbeing
"Fast" caffeine metabolizers:
• Homozygous for the wild type CYP1A2*1A/*1A
• Risk of nonfatal heart attack is reduced by 22% when drinking 2-3 cups of coffee per day; while
drinking 4 or more cups has no effect [1].
• "Fast" caffeine metabolizers may benefit more than "slow" caffeine metabolizers when drinking
coffee in moderation as part of their daily lifestyle because of several health benefits of antioxidants found in coffee
Laboratory Cytochrome P450 1A2 alleles tested:
• Slow variant: 1 copy of CYP1A2*1F (dominant)
Laboratory specimens were analyzed using Allelic Specific Amplification with Real-Time PCR Quantitative Analysis. Disclaimer
All materials and products provided by Consumer Genetics, Inc. are provided for informational and educational purposes only, and are not intended for diagnosis and/or treatments of any diseases or disorders. Clients should consult with their own physicians and health care providers for any health and medical needs. Consumer Genetics, Inc. is not liable for any actions that might be taken by users of this service. Consumer Genetics, Inc. shall not be held liable for any damages caused as a result of the use of the information or products contained herein. In order to maintain the quality and accuracy of Consumer Genetics' service, the test instructions must be followed precisely. [1]. Cornelis MC, et al. JAMA 2006; 295: 1135-1141
Be Active : An Economic Appraisal April 2006 P.R. Myles Executive Summary This report is an economic appraisal of the physical activity referral programme ‘Be Active’. The aim is to determine whether the benefits of the ‘Be Active’ programme outweighed the costs. A cost-consequences analysis (CCA) has been carried out which provides detailed costing of the proj
The information in this document is supplied solely as a resource for journalists. Any questions about your veterinary healthcare or treatment should be The QUEST trial is the largest global clinical study of its kind ever to be conducted amongst dogs with congestive heart failure. QUEST stands for Qu ality of Life and E xtension of S urvival T ime, and was an international, multi- ce